Health Interests

Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases

February 22, 2018

Cambridge, Ma., Redmond, Wash., and Brussels, Belgium – February 20, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), Microsoft and EURORDIS-Rare Diseases Europe today announced a strategic alliance to address the diagnostic challenge for patients living with a rare disease. The long road to diagnosis is one of the most important issues affecting the health, […]

Noventure and Laboratorios Salvat enter into agreement to commercialise innovative medical device in Spain and Portugal for rhinitis and rhinosinusitis

February 21, 2018

The agreement will see the global launch of Noventure’s novel nasal mucoprotection product  Barcelona, Spain, February 21, 2018 – Noventure and Laboratorios Salvat, S.A. (Salvat), announce today that they have entered into an agreement in which Salvat will distribute Noventure’s nasal mucoprotection product in Spain and Portugal. The product contains a mucomimetic agent that forms […]

Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®

February 21, 2018

Amneal Pharmaceuticals has launched memantine hydrochloride extended-release capsules, the company’s AB-rated equivalent for Namenda XR®, in 7 mg, 14 mg, 21 mg and 28 mg strengths. The product is manufactured here in the United States in the company’s recently expanded Brookhaven, New York facility. Annual U.S. sales of Namenda XR® were $929 million, according to […]

Wout Brusselaers to Speak at HIMSS18 on Finding the Return on Investment of Artificial Intelligence

February 14, 2018

HIMSS has named Wout Brusselaers, chief executive officer of Deep 6 AI , an artificial intelligence (AI) company focused on accelerating patient recruitment for clinical trials, as a speaker for the 2018 HIMSS Conference & Exhibition (HIMSS18). Brusselaers will co-present the “Finding the ROI of AI” educational session with Bobbie J. Rimel, MD, gynecologic oncologist and associate director for gynecological […]

Circassia Receives Innovative Technology Contract from Vizient, Inc. for NIOX VERO® Asthma Management Products

February 8, 2018

(MORRISVILLE, NC) – Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announces that it has received a multi-year Innovative Technology contract for its NIOX VERO® asthma management products from Vizient, Inc., the largest member-owned health care company in the United States.  The contract was based on the […]

ERT Expands Respiratory Solutions to Support New Endpoints

February 8, 2018

ERT Expands Respiratory Solutions to Support New Endpoints Industry-leading MasterScope™ integration provides centralized Forced Oscillation Technique services to deliver high quality data while lessening patient and site burden PHILADELPHIA – February 8, 2018 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced advanced respiratory clinical trial […]

iX Biopharma Secures China Patent for WaferiX Drug Delivery Technology

February 8, 2018

Singapore, 8 February 2018 – iX Biopharma Ltd. (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that it has been granted a patent for its WaferiX drug delivery technology by the People’s Republic of China (Patent No. ZL 2013800602813). The patent, which expires on 11 October 2033, allows iX Biopharma […]

FEEDBACK